<DOC>
	<DOCNO>NCT01960946</DOCNO>
	<brief_summary>This study investigate Modified Citrus Pectin ( MCP ) help people high blood pressure . MCP dietary supplement derive plant , therefore subject approval U.S. Food Drug Administration ( FDA ) . However , MCP deem 'generally regarded safe ' FDA . This study examine whether Modified Citrus Pectin ( MCP ) help people high blood pressure . The study help understand MCP may affect risk heart disease patient high blood pressure .</brief_summary>
	<brief_title>Galectin-3 Blockade Patients With High Blood Pressure</brief_title>
	<detailed_description>Gal-3 appear potential mediator cardiac fibrosis , precede development clinical heart failure . In study , seek identify individual risk development heart failure base clinical hypertension elevate Gal-3 concentration . Participants randomize receive Gal-3 inhibitor ( MCP ) placebo . The primary outcome effect collagen metabolism , secondary outcome include echocardiographic measure cardiac structure function , non-invasive measure vascular function .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Pectin</mesh_term>
	<criteria>Age 2170 year Physician diagnose hypertension stable therapy 3 month Elevated galectin3 level ( sexspecific median base Framingham Heart Study measure ) Able understand protocol provide inform consent English Uncontrolled hypertension , define systolic blood pressure &gt; 170mmHg , diastolic blood pressure &gt; 100mmHg Evidence secondary hypertension History heart failure , coronary artery disease , stroke , atrial fibrillation Left ventricular ejection fraction &lt; 45 % echocardiography Use aldosterone antagonist History liver cirrhosis History pulmonary fibrosis Kidney dysfunction , define estimate glomerular filtration rate &lt; 45 ml/min/1.73m2 Anemia , define hematocrit &lt; 38 % men &lt; 36 % woman Use chelate agent History cancer malignancy Known pregnancy , unwilling avoid pregnancy course study , woman currently breastfeed Hyperkalemia screen lab , define potassium &gt; 5.0 Anticipated inability complete comply study protocol History angioedema</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Galectin 3</keyword>
	<keyword>Fibrosis</keyword>
	<keyword>Vascular Stiffness</keyword>
	<keyword>Echocardiography</keyword>
</DOC>